These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
302 related articles for article (PubMed ID: 19132003)
1. Photodynamic therapy for prostate cancer--a review of current status and future promise. Moore CM; Pendse D; Emberton M Nat Clin Pract Urol; 2009 Jan; 6(1):18-30. PubMed ID: 19132003 [TBL] [Abstract][Full Text] [Related]
2. Updated results of a phase I trial of motexafin lutetium-mediated interstitial photodynamic therapy in patients with locally recurrent prostate cancer. Verigos K; Stripp DC; Mick R; Zhu TC; Whittington R; Smith D; Dimofte A; Finlay J; Busch TM; Tochner ZA; Malkowicz S; Glatstein E; Hahn SM J Environ Pathol Toxicol Oncol; 2006; 25(1-2):373-87. PubMed ID: 16566729 [TBL] [Abstract][Full Text] [Related]
3. Photodynamic therapy using meso tetra hydroxy phenyl chlorin (mTHPC) in early prostate cancer. Moore CM; Nathan TR; Lees WR; Mosse CA; Freeman A; Emberton M; Bown SG Lasers Surg Med; 2006 Jun; 38(5):356-63. PubMed ID: 16392142 [TBL] [Abstract][Full Text] [Related]
4. Vascular-targeted photodynamic therapy with TOOKAD® Soluble in localized prostate cancer: standardization of the procedure. Azzouzi AR; Lebdai S; Benzaghou F; Stief C World J Urol; 2015 Jul; 33(7):937-44. PubMed ID: 25786708 [TBL] [Abstract][Full Text] [Related]
5. Photosensitizers in prostate cancer therapy. Gheewala T; Skwor T; Munirathinam G Oncotarget; 2017 May; 8(18):30524-30538. PubMed ID: 28430624 [TBL] [Abstract][Full Text] [Related]
6. Photodynamic therapy for prostate cancer recurrence after radiotherapy: a phase I study. Nathan TR; Whitelaw DE; Chang SC; Lees WR; Ripley PM; Payne H; Jones L; Parkinson MC; Emberton M; Gillams AR; Mundy AR; Bown SG J Urol; 2002 Oct; 168(4 Pt 1):1427-32. PubMed ID: 12352410 [TBL] [Abstract][Full Text] [Related]
7. Photodynamic therapy for prostate cancer--an emerging approach for organ-confined disease. Moore CM; Emberton M; Bown SG Lasers Surg Med; 2011 Sep; 43(7):768-75. PubMed ID: 22057504 [TBL] [Abstract][Full Text] [Related]
8. Photodynamic therapy for focal ablation of the prostate. Arumainayagam N; Moore CM; Ahmed HU; Emberton M World J Urol; 2010 Oct; 28(5):571-6. PubMed ID: 20454966 [TBL] [Abstract][Full Text] [Related]
9. Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial. Azzouzi AR; Vincendeau S; Barret E; Cicco A; Kleinclauss F; van der Poel HG; Stief CG; Rassweiler J; Salomon G; Solsona E; Alcaraz A; Tammela TT; Rosario DJ; Gomez-Veiga F; Ahlgren G; Benzaghou F; Gaillac B; Amzal B; Debruyne FM; Fromont G; Gratzke C; Emberton M; Lancet Oncol; 2017 Feb; 18(2):181-191. PubMed ID: 28007457 [TBL] [Abstract][Full Text] [Related]
10. Preclinical studies in normal canine prostate of a novel palladium-bacteriopheophorbide (WST09) photosensitizer for photodynamic therapy of prostate cancers. Chen Q; Huang Z; Luck D; Beckers J; Brun PH; Wilson BC; Scherz A; Salomon Y; Hetzel FW Photochem Photobiol; 2002 Oct; 76(4):438-45. PubMed ID: 12405153 [TBL] [Abstract][Full Text] [Related]
11. Treatment of localized prostate cancer using WST-09 and WST-11 mediated vascular targeted photodynamic therapy-A review. Kawczyk-Krupka A; Wawrzyniec K; Musiol SK; Potempa M; Bugaj AM; Sieroń A Photodiagnosis Photodyn Ther; 2015 Dec; 12(4):567-74. PubMed ID: 26467273 [TBL] [Abstract][Full Text] [Related]
12. Determination of optimal drug dose and light dose index to achieve minimally invasive focal ablation of localised prostate cancer using WST11-vascular-targeted photodynamic (VTP) therapy. Moore CM; Azzouzi AR; Barret E; Villers A; Muir GH; Barber NJ; Bott S; Trachtenberg J; Arumainayagam N; Gaillac B; Allen C; Schertz A; Emberton M BJU Int; 2015 Dec; 116(6):888-96. PubMed ID: 24841929 [TBL] [Abstract][Full Text] [Related]
13. Diverse optical characteristic of the prostate and light delivery system: implications for computer modelling of prostatic photodynamic therapy. Jankun J; Keck RW; Skrzypczak-Jankun E; Lilge L; Selman SH BJU Int; 2005 Jun; 95(9):1237-44. PubMed ID: 15892808 [TBL] [Abstract][Full Text] [Related]